Eve Dias, our ESR5, starts her secondment at Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Germany

Eve Dias has just left the Institute of Josep Carreras in Spain to start her secondment in the lab of Hind Medyouf at the Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Germany.

In her current work, Eve focuses on the mutations of STAG2, a core component of the cohesin complex. She tries to understand how these mutations impact the patients with Myelodysplastic Syndromes (MDS).

 In Hind Medyouf’s lab, she will learn to work with 2D co-culture and 3D cell culture models. Her aim is to use these techniques to understand why MDS patients with STAG2 mutations show poor prognosis and why their condition transforms rapidly to secondary acute myeloid leukemia.